Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie - Czech Republic
doi 10.14735/amko2016342
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ambit Media, a.s.

Related search

Treatment of Relapse and Refractory Hodgkin Lymphoma

Oncogematologiya
OncologyHematology
2017English

Treating Hodgkin Lymphoma in the New Millennium: Relapsed and Refractory Disease

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The Role of Cytotoxic and Regulatory T Cells in Relapsed/Refractory Hodgkin Lymphoma

Applied Immunohistochemistry and Molecular Morphology
Forensic MedicinePathologyMedical Laboratory TechnologyHistology
2010English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

Blood Reviews
OncologyHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy